Ticagrelor Tablet, Film Coated
Product Images NDC 70756-047

This is not readable.*

This text provides data on a study comparing the effects of Ticagrelor 90 mg bd and Placebo in a research setting. The study recorded the number of events (28 in the Ticagrelor group and 7 in the Placebo group) out of the total number of participants in each group (5523 and 5493, respectively). The Kaplan-Meier percentage for events is 0.5% for Ticagrelor and 0.1% for Placebo. Additionally, it gives cumulative percentages over time and lists days from randomization. The data seems to be part of a larger study or clinical trial analysis.*

This provided text appears to show different intrinsic factors and their effects on dose adjustments for the medication Ticagrelor AR-C124910XX. The factors evaluated include age, gender, ethnicity, renal impairment, end stage renal disease, and hepatic impairment. The analysis seems to present recommendations on whether dose adjustment is needed based on these intrinsic factors. Additionally, there is mention of the mean effect and 90% confidence interval. The provided data may be part of a study or medical guideline.*

This document provides recommendations for interacting drugs with Ticagrelor AR-G124910XX based on their impact on CYP3A4 enzymes. It categorizes drugs into strong, moderate, and potent CYP3A4 inhibitors, and inducers, specifying whether to avoid concomitant use or if dose adjustments are needed. Descriptions such as dose adjustments and the effect of P-gP and GYP3A inhibitors are included for various medications, including Ketocanazole, Diliazem, and Aspirin. The text also mentions drugs like Cyclosporine and Morphine, indicating specific sections for further information. Ratios for pharmacokinetic parameters such as Cmax and AUC are discussed along with relative changes to the reference.*

This text provides a list of interacting drugs with Ticagrelor and recommended dose adjustments. It includes information on medications like Simvastatin, Atorvastatin, Levonorgestrel, Ethinyl Estradiol, Tolbutamide, Digoxin, and Cyclosporine. The document specifies the recommended doses of Ticagrelor in combination with each of these drugs.*

The provided text seems to be a statistical analysis or report comparing the characteristics of patients taking Ticagrelor versus Placebo in a clinical trial. The data includes variables such as age, sex, race, weight, BMI, geographic region, diagnosis of index event, time from index event to randomization, diabetes mellitus, hypertension, prior stroke or TIA, prior ischemic heart disease, prior ASA use, statin treatment history, and smoking status. The analysis calculates hazard ratios (HR) with 95% confidence intervals for each characteristic to evaluate the effectiveness of Ticagrelor versus Placebo. It provides insights into how each factor may impact the outcomes of patients. It is a detailed comparison to determine the efficacy of Ticagrelor in the given patient populations.*

This text provides information about Ticagrelor tablets containing 60 mg of the active ingredient. It includes instructions for pharmacists to dispense the provided Medication Guide, dosage details for adults, storage conditions, and warnings regarding child safety. The tablets are manufactured for Lifestar Pharma LLC in the USA but made in India. The text also contains a weblink to access the Medication Guide online, along with manufacturing and expiration date details.*

This text provides information about a medication called ticagrelor in the form of film-coated tablets, each containing 90 mg of the active ingredient. It also includes the manufacturer's details, dosage instructions, storage conditions, a warning about keeping the medication out of reach of children, and a reference to a medication guide available online. The medication is manufactured in India and is distributed by Lifestar Pharma LLC based in Mahwah, NJ, USA.*

This text contains information about Ticagrelor tablets with a dosage of 90 mg and 50 mg. The tablets are to be dispensed by a pharmacist along with a Medication Guide provided separately to each patient. The tablets come in a pack of 100 (10 x 10) unit-dose tablets. The usual adult dosage is specified in the package insert. The tablets should be stored at a temperature range of 20°C to 25°C (68°F to 77°F), with excursions permitted to 16°C to 30°C (59°F to 86°F). The manufacturer is Lifestar Pharma LLC located in Mahwah, NJ, USA, and the tablets are made in India.*

This text mentions the drug Ticagrelor in tablet form, a prescription medication used in the treatment of certain heart conditions. It appears to include information about the manufacturer or supplier.*